Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pvs230D1-EPA + Matrix-M
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Pvs230D1-EPA + Matrix-M is a transmission-blocking vaccine candidate for Plasmodium vivax malaria. It consists of Pvs230 domain 1 (Pvs230D1), a recombinant protein from subdomain 1 of native Pvs230 (Val-226 to Gly-427) produced in Pichia pastoris, chemically conjugated to Exoprotein A (EPA) and combined with Matrix-M adjuvant. The vaccine is designed to induce antibodies that can block the transmission of malaria parasites from humans to mosquitoes, thereby interrupting the malaria transmission cycle. It is being developed by the National Institute of Allergy & Infectious Diseases (NIAID).
02
Targets
Pvs230D1 (Pvs230 domain 1)
Beyond the preview
Go deeper on Pvs230D1-EPA + Matrix-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pvs230D1-EPA + Matrix-M.